{
  "id": "63eeeb70f36125a426000005",
  "type": "factoid",
  "question": "What disease can be treated with Glofitamab?",
  "ideal_answer": "Glofitamab is being tested for treatment of DLBCL after CAR T-Cell Therapy",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
    "http://www.ncbi.nlm.nih.gov/pubmed/34941996",
    "http://www.ncbi.nlm.nih.gov/pubmed/36198538"
  ],
  "snippets": [
    {
      "text": "Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626120",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36198538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34941996",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "DLBCL"
}